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response rate of the AUC ≥ 4 group was significantly 
higher than that of the AUC < 4 group. Decreased platelet 
and neutrophil counts of grade ≥3 occurred at higher rates 
in the AUC ≥ 4 group.
Conclusion The extrapolation of the Calvert formula has 
utility in calculating the CBDCA dosage for DeVIC ± R 
therapy, and therapeutic efficacy was increased by main-
taining the AUC of CBDCA at ≥4.
Keywords DeVIC ± R therapy · Dose calculation 
method · CBDCA · Non-Hodgkin lymphoma · Calvert 
formula
Introduction
Carboplatin (CBDCA), a type of platinum-containing drug, 
is widely used in the treatment of non-small cell lung can-
cer, ovarian cancer, cervical cancer and malignant lym-
phoma [1]. CBDCA is predominantly excreted by the kid-
neys, with approximately 70 % eliminated in the urine [2]. 
Accordingly, the Calvert formula
has demonstrated utility in calculating CBDCA dosage as 
it takes into account individual differences in renal function 
[3]. The utility of this method has also been documented 
in studies of Japanese patients [4]. CBDCA is rarely used 
in single-agent therapy. However, a combination therapy 
of CBDCA and paclitaxel (TC therapy) is used to treat 
ovarian cancer, and a combination therapy of CBDCA and 
dose (mg) = target area under the curve (AUC)
× (glomerular filtration rate+ 25)
Abstract 
Purpose Several studies have evaluated the utility of 
extrapolating the Calvert formula in calculating carbo-
platin (CBDCA) dosages in solid tumours; however, data 
regarding haematological cancers are less. Therefore, we 
conducted a preliminary study of the utility of extrapolat-
ing the Calvert formula in calculating CBDCA dosages for 
DeVIC ± R therapy.
Methods A retrospective study on 57 non-Hodgkin lym-
phoma patients who had received DeVIC ± R therapy was 
conducted. The area under the curve (AUC) of CBDCA 
was back-calculated from actual dosages using the Calvert 
formula. Patients were divided into two groups according 
to an AUC ≥ 4 or an AUC < 4, respectively. The Revised 
Response Criteria of the International Working Group and 
CTCAE version 4.0 were used for assessing the treatment 
efficacy and adverse events, respectively.
Results The use of AUC instead of body surface area 
had greater utility in calculating CBDCA dosage, with 
a response rate of greater than 50 % in patients receiving 
DeVIC ± R therapy with an AUC ≥ 4 for CBDCA. The 
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pemetrexed is used to treat non-small cell lung cancer. In 
both cases, the Calvert formula is used to calculate CBDCA 
doses, with a target AUC of 5.0–7.5 [5] for TC therapy and 
6 for CBDCA + PEM therapy [6] shown to be adequate.
DeVIC ± R therapy [7], ESHAP ± R therapy [8–10], 
EPOCH ± R therapy [11–13], ICE ± R therapy [14–17] 
and CHASE ± R therapy [18, 19] are often administered as 
salvage therapies for non-Hodgkin lymphoma, a type of hae-
matological cancer, in Japan [20]. However, there is little evi-
dence comparing the efficacies of each therapeutic regime. 
As a result, therapy is often chosen depending on the clini-
cal condition of individual patients. DeVIC therapy, devel-
oped by Okamoto et al., combines dexamethasone (DEX), 
etoposide (ETP), ifosfamide (IFO) and CBDCA as a salvage 
therapy for recurrent or treatment-resistant non-Hodgkin lym-
phoma [7]. This therapy is unique in that it does not contain 
vincristine (VCR), doxorubicin (DXR) and cyclophospha-
mide (CPA), which are the components of CHOP therapy 
[21–23], generally considered the first-line therapy for non-
Hodgkin lymphoma. DeVIC therapy is administered every 
21 days for at least four cycles. The body surface area method 
has demonstrated utility in CBDCA dose calculation in 
DeVIC ± R therapy. Moskowitz et al. [15] reported response 
rate of 66.3 % when the target AUC of CBDCA was set at 5 
in ICE therapy used for the treatment of non-Hodgkin lym-
phoma prior to peripheral blood stem cell transplantation and 
further demonstrated the utility of the Calvert formula in cal-
culating the CBDCA dosage for haematological cancers. The 
present study included patients with non-Hodgkin lymphoma 
who had received DeVIC ± R therapy and was designed to 
retrospectively evaluate the AUC of CBDCA dosage (based 
on body surface area) administered using the Calvert formula 
and elucidate the relationship between AUC, therapeutic effi-
cacy and adverse events. Accordingly, this was a preliminary 
study to determine the utility of the Calvert formula in calcu-
lating the CBDCA dosage for DeVIC therapy.
Methods
Patients
Patients included patients with relapsed or refractory non-
Hodgkin lymphoma receiving DeVIC ± R as the ini-
tial therapy between January 2005 and March 2014 at the 
Department of Hematology, Fujita Health University Hos-
pital. Patients with diseases other than non-Hodgkin lym-
phoma or those who did not receive more than one course 
of treatment were excluded. Patients with a creatinine clear-
ance (CrCl) of >125 mL/min were excluded as CBDCA 
dosages may be overestimated by the Calvert formula in 
patients with abnormally low serum creatinine levels [24]. 
For DeVIC therapy, 40 mg/body of DEX, 1500 mg/m2 of 
IFO and 100 mg/m2 of ETP were each intravenously admin-
istered between days 1 and 3, and 300 mg/m2 of CBDCA 
was intravenously administered on day 1. Furthermore, 
375 mg/m2 of rituximab was intravenously administered 
one day prior to the commencement of DeVIC therapy for 
the treatment of B-cell non-Hodgkin lymphoma. IFO, ETP 
and CBDCA dosages were reduced to 1000, 70 and 200 mg/
m2, respectively, in patients aged 70 years or greater.
Investigations
This was a retrospective study based on patient data col-
lected from electronic patient files available in the databases 
of Fujita Health University Hospital. Surveyed parameters at 
treatment initiation included the following: age; gender; body 
surface area; histological images of lymphocytes; serum cre-
atinine levels; platelet counts; haemoglobin (Hb) levels; neu-
trophil counts; dosages of CBDCA, IFO, ETP and DEX; and 
protocols for CBDCA dosing according to body surface area 
as indicated in the medical package insert of CBDCA. Sur-
veyed items following the first cycle of DeVIC ± R therapy 
consisted of nadir of platelet counts, Hb levels, neutrophil 
counts and the occurrence and severity of thrombocytopae-
nia, anaemia and neutropaenia. CrCl was calculated using the 
Cockcroft and Gault method on the basis of peripheral blood 
serum creatinine levels. AUC values for CBDCA back-calcu-
lated from the actual administered dosage were used in the 
calculation formula shown below.
The present study was conducted according to protocols 
approved by the Fujita Health University School of Medicine 
Epidemiological and Clinical Research Ethics Committee.
Assessment
AUC was back-calculated using the Calvert formula on the 
basis of CBDCA dosages administered to patients receiv-
ing DeVIC ± R therapy. Patients were divided into two 
groups according to the calculated AUC, one group with 
AUC ≥ 4 and the other with AUC < 4, to compare treat-
ment efficacy and safety. The International Working Group 
(IWG) Revised Response Criteria [25] were used to assess 
treatment efficacy after the final cycle. The National Can-
cer Institute—Common Terminology Criteria for Adverse 
Events version 4.0 was used to determine adverse events 
following the first cycle.
Statistical analysis
Variables exhibiting a normal distribution were expressed 
as means ± standard deviations. Variables not exhibiting a 
normal distribution were given as medians with interquartile 
AUC of CBDCA = Dose of carboplatin (mg)/(CrCl+ 25)
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ranges. For comparison of values between the two groups, 
the unpaired t test was used for normally distributed vari-
ables, whereas the Mann–Whitney U test was used for non-
normally distributed variables. The Chi-square test was used 
for ratio comparisons between the groups. For comparison 
of values between patients, the paired t test was used for nor-
mally distributed variables and the Wilcoxon signed-rank test 
was used for non-normally distributed variables. The Spear-
man’s rank correlation coefficient was used to study the cor-
relation between AUC, actual dosage and therapeutic effi-
cacy. Therapeutic efficacy was scored as follows: 4 points for 
complete response (CR), 3 points for partial response (PR), 
2 points for stable disease (SD) and 1 point for progressive 
disease (PD). Univariate analysis was performed to identify 
factors influencing therapeutic efficacy in terms of CR or 
PR. Multivariate logistic regression analysis was performed 
for items with a risk rate of 10 % and below. The Hosmer–
Lemeshow statistical test was used to validate the goodness 
of fit of the developed model. The Statistical Package for 
the Social Sciences (SPSS) version 22.0 (IBM Corporation, 
Armonk, NY, USA) was used for all statistical analyses. P 
values of <0.05 were considered statistically significant.
Results
Patient selection
We identified a total of 70 patients during the survey 
period. Of these, 13 patients were excluded: 6 with a CrCl 
of >125 mL/min, 3 with Hodgkin lymphoma, 1 with mul-
tiple myeloma, 1 who did not receive more than one treat-
ment course and 2 with missing data. Accordingly, 57 
patients were included in the final study sample.
Validation of CBDCA dose calculation according to the 
AUC method
No significant difference was observed between the pro-
tocol dosage (median, 342 mg; range, 290–437 mg) and 
actual administered dosage (median, 336 mg; range, 300–
420 mg; P = 0.309; Wilcoxon signed-rank test). In com-
parison, the AUC values back-calculated from the actual 
administered dosages (3.78 ± 0.95 min mg/mL) were 
significantly lower than the AUC values back-calculated 
from the protocol dosages (3.99 ± 0.73 min mg/mL; 
P = 0.038; paired t test). No significant differences in 
actual dosage or therapeutic efficacy were observed when 
the CR and PR groups (median, 247 mg/m2; range, 199–
302 mg/m2) were compared with the PD and SD groups 
(median, 214 mg/m2; range, 194–299 mg/m2; P = 0.275; 
Wilcoxon signed-rank test). AUC values back-calculated 
from the actual administered dosage and therapeutic 
efficacy demonstrated that the AUC of the CR and PR 
groups (4.16 ± 0.88) was significantly higher than that of 
the PD and SD groups (3.53 ± 0.92; P = 0.013; unpaired 
t test). Furthermore, no correlation was observed between 
actual dosage and therapeutic efficacy when the two 
parameters were plotted with 4 as the maximum number 
of points for therapeutic efficacy (ρ = 0.165, P = 0.220; 
Spearman’s rank correlation coefficient). A weak corre-
lation was observed between AUC and therapeutic effi-
cacy (ρ = 0.302, P = 0.022; Spearman’s rank correlation 
coefficient).
Group assignment
Table 1 shows the relationship between AUC values back-
calculated from protocol dosages and response rate. A 
value of 4 was set as the AUC cut-off limit to divide the 
patients into two groups, according to response rates of 
more or <50 % to compare treatment efficacy. A total of 22 
patients had an AUC ≥ 4 and 35 patients had an AUC < 4. 
Table 2 shows the baseline characteristics of the AUC ≥ 4 
and AUC < 4 groups. Study parameters for which a signifi-
cant difference between the groups was observed included 
body surface area, CrCl, CBDCA dosage, AUC back-calcu-
lated from the actual administered CBDCA dosage, actual 
CBDCA dosage divided by protocol CBDCA dosage and 
IFO and ETP dosages.
Table 1  Relationship between 
AUC and response rate
AUC area under the blood concentration–time curve, CBDCA carboplatin, CR complete response, PR par-
tial response, SD stable disease, PD progressive disease
AUC of CBDCA dosage Total Effective (CR or PR) Non-effective (SD or PD) Response rate (%)
<2.5 4 0 4 0
2.5–<3.0 9 3 6 33.3
3.0–<3.5 11 2 9 18.2
3.5–<4.0 11 5 6 45.5
4.0–<4.5 8 4 4 50.0
4.5–<5.0 10 7 3 70.0
≥5.0 4 2 2 50.0
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Therapeutic efficacy
The proportion of patients evaluated as having CR or PR 
in the AUC < 4 group was 28.6 %. In contrast, the cor-
responding proportion in the AUC ≥ 4 group was sig-
nificantly higher (59.1 %; Fig. 1). Of these patients, the 
proportions receiving rituximab for B-cell non-Hodgkin 
lymphoma were 70.0 and 76.9 % for the AUC < 4 and 
AUC ≥ 4 groups, respectively (P = 0.71). The proportion 
of patients receiving rituximab evaluated as having CR or 
PR was significantly higher in the AUC ≥ 4 group (83.3 %) 
than in the AUC < 4 group (43.8 %; P = 0.034; χ2 test). 
Multivariate logistic regression analysis demonstrated a 
high AUC of CBDCA could become recognized as the fac-
tor independently associated with therapeutic efficacy in 
terms of CR or PR (Table 3). Rituximab administration and 
the number of DeVIC treatment courses were found to be 
strongly associated with therapeutic efficacy. On the other 
hand, age greater than or equal to 70 years, CBDCA dos-
age per body surface area and IFO and ETP dosage were 
not be associated with therapeutic efficacy.
Haematotoxicity
To validate the haematotoxicity of DeVIC ± R therapy, 
baseline and nadir of platelet counts, Hb levels and neutro-
phil counts and frequency of haematotoxicity were inves-
tigated. Comparisons of data before and after treatment 
demonstrated that all values in both groups significantly 
Table 2  Patient characteristics 
before DeVIC ± R therapy
DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, ENKL extranodal NK/T cell lymphoma, 





<4 (n = 35) ≥4 (n = 22)
Age 67.8 ± 11.3 67.6 ± 11.9 68.0 ± 10.5 0.88
Male gender (%) 57.9 60.0 54.5 0.68
Body surface area (m2) 1.44 ± 0.15 1.40 ± 0.14 1.49 ± 0.13 0.04
Histology (%)
  DLBCL 63.2 74.3 45.5 0.12
  FL 8.8 5.7 13.6
  ENKL 5.3 5.7 4.5
  Others 24.6 14.3 40.9
Creatinine clearance (mL/min) 67.4 ± 19.9 71.8 ± 21.1 60.4 ± 15.8 0.023
Course number of DeVIC 2.4 ± 1.3 2.2 ± 1.2 2.6 ± 1.4 0.18
CBDCA
  Dosage (mg) 336 (150–490) 300 (150–480) 412 (250–490) 0.0001
               (mg/m2) 229 (109–328) 210 (109–310) 298 (191–328) <0.0001
  AUC (min·mg/mL) 3.78 ± 0.95 3.17 ± 0.55 4.76 ± 0.54 <0.0001
  Actual dosage / protocol dosage 0.95 ± 0.19 0.88 ± 0.03 1.06 ± 0.02 0.0039
Dosage of IFO (mg/m2) 1225 ± 257 1159 ± 242 1330 ± 248 0.014
Dosage of ETP (mg/m2) 82.2 ± 18.0 76.5 ± 15.0 91.2 ± 18.0 0.0017
Dosage of dexamethasone (%)
  40 mg/body 77.2 71.4 86.4 0.19
  <40 mg/body 22.8 28.6 13.6
Rituximab combined therapy (%) 49.1 45.7 54.5 0.52















Fig. 1  Percentage of patients with positive effect resulting in CR or 
PR for non-Hodgkin lymphoma after the final cycle of DeVIC ± R 
therapy. CR complete response, PR partial response, CBDCA carbopl-
atin, AUC area under the blood concentration–time curve
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declined (data not shown). Comparison of post-treatment 
haematological toxicities between the two groups dem-
onstrated significantly lower neutrophil counts in the 
AUC ≥ 4 group than in the AUC < 4 group (Table 4). 
Analysis of the frequency of grade ≥3 haematotoxic-
ity demonstrated a higher frequency of thrombocytopae-
nia and neutropaenia of grade ≥3 in the AUC ≥ 4 group 
than the AUC < 4 group (Table 5). The frequency of febrile 
neutropaenia was 22.7 % in the AUC ≥ 4 group and 25.7 % 
in the AUC < 4 group, with no statistically significant dif-
ference observed between the two groups (P = 0.80). 
Additionally, the frequency of grade 4 neutropaenia was 
95.5 % in the AUC ≥ 4 group and 65.7 % in the AUC < 4 
group, with a statistically significant difference observed 
between the two groups (P = 0.009). The frequency of 
grade 4 thrombocytopaenia was 45.5 % in the AUC ≥ 4 
group and 37.1 % in the AUC < 4 group, with no statis-
tically significant difference observed between the two 
groups (P = 0.53). No patient developed grade 4 anaemia 
during the present study. Multivariate logistic regression 
analysis did not demonstrate an association between AUC 
of CBDCA and grade 4 haematological toxicity (data not 
shown).
Discussion
In Japan, medical package inserts for CBDCA recommend 
a dose calculation method according to the body surface 
area. However, recent studies [5, 6, 15] have reported the 
utility of extrapolating the Calvert formula in calculat-
ing the dosage of CBDCA. Therefore, we performed the 
present preliminary study to evaluate whether the Calvert 
formula can be extrapolated for CBDCA dose calculation 
in DeVIC ± R therapy. As a result, we demonstrate the 
greater utility of calculating CBDCA dosage according to 
AUC instead of body surface area. A pilot study of DeVIC 
therapy reported that the CR rate is 24 % for a CBDCA 
dosage of 300 mg/m2 (reduced for patients aged 70 years 
or older) [7], with a mean CR rate among all study indi-
viduals of 26.3 %, comparable to that observed in the pre-
sent study. However, the CR rate for the AUC ≥ 4 group 
was substantially higher (36.0 %). We were able to validate 
the increase in therapeutic efficacy by setting the AUC of 
CBDCA at ≥4, with a significantly higher response rate 
(59.1 %) obtained compared to that in the AUC < 4 group. 
Furthermore, rituximab was found to have a synergistic 
effect.
Patient profiles at baseline were characterized by sev-
eral factors that may influence the results of comparisons 
between the AUC < 4 and AUC ≥ 4 groups. Therefore, 
multivariate logistic regression analysis was performed to 
identify factors associated with therapeutic efficacy, which 
thus influence CR and PR. Following this analysis, a high 
AUC of CBDCA could become recognized as the factor 
independently associated with therapeutic efficacy. Cre-
atinine clearance may not have been identified as a factor 
associated with therapeutic efficacy on multivariate logistic 
regression analysis because the concentration of CBDCA 
dosage determined from the body surface area regardless 
of creatinine clearance was sufficient to render therapeutic 
Table 3  Factors influencing therapeutic efficacy resulting in CR or 
PR for non-Hodgkin lymphoma after the final cycle of DeVIC ± R 
therapy
Effective factors are analysed with multivariable logistic regression 
models
CR complete response, PR partial response, DLBCL diffuse large 
B-cell lymphoma, FL follicular lymphoma, CBDCA carboplatin, 
AUC area under the blood concentration–time curve, IFO ifosfamide, 
ETP etoposide
Hosmer–Lemeshow test, P = 0.88
Univariate analysis Multivariate analysis
Odds ratio 
(95 % CI)
P value Odds ratio 
(95 % CI)
P value
Age ≥ 70 years 0.42 0.12
(0.14–1.26)
Male gender 0.68 0.47
(0.23–1.97)














AUC of CBDCA 
(min·mg/mL)







Dosage of IFO (mg/m2) 1.00 0.44
(0.99–1.00)








5.92 0.003 39.24 0.023
(1.83–19.20) (1.68–>50)
Course number of 
DeVIC
12.00 <0.001 81.12 0.007
(3.49–41.26) (3.27–>50)
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effects. On the other hand, rituximab administration and 
the number of DeVIC treatment courses were found to be 
strongly associated with therapeutic efficacy. However, 
these results demonstrate the AUC of CBDCA, calculated 
by the extrapolation of the Calvert formula, was taken into 
consideration although the influence of other factors (such 
as rituximab administration and the number of DeVIC 
treatment courses) was strong. Although the results of the 
present study demonstrate the validity of CBDCA dose 
calculation according to the AUC method, the low number 
of patients included in the multivariate logistic regression 
analysis may have reduced the statistical power. As men-
tioned in the introduction, there is little evidence regarding 
the efficacy of individual salvage therapies, and it is con-
ventional practice for therapies to be chosen at the physi-
cian’s discretion depending on the patient’s clinical condi-
tion; therefore, it is difficult to make a direct comparison of 
effectiveness. Nevertheless, the CR rate when calculating 
CBDCA dosage per body surface area for DeVIC ± R ther-
apy (26.3 %) was inferior to that for DHAP therapy (31 %) 
developed around the same time [26] and ESHAP therapy 
(37 %) [8]. In contrast, the CR rate could be improved to 
36 % in the present study by setting the AUC at ≥4 and 
extrapolating the Calvert formula for CBDCA dosage cal-
culation. Furthermore, we demonstrated the validity of 
CBDCA dose calculation according to the AUC method. 
Jodrell et al. [27] studied single-agent CBDCA therapy in 
1028 ovarian cancer patients and demonstrated a positive 
correlation between response rates and an AUC of up to 
5; however, the increase in response rate diminished after 
AUC values became >5. The sample size in the present 
study was small; therefore, we were unable to identify a 
specific upper limit of the AUC. The use of ESHAP therapy 
remains controversial as the addition of rituximab has no 
effect on overall response rate, CR rate or actuarial curves 
at 5 years [10]. On the other hand, the CR rate for ICE 
therapy without rituximab has been reported as 27 %; how-
ever, a significantly higher CR rate (53 %) was observed 
with the addition of rituximab [16]. Accordingly, rituximab 
appears to have varying effects depending on the treat-
ment method. As demonstrated by the results of the present 
study, response rates may be improved by the addition of 
rituximab when choosing DeVIC therapy for B-cell malig-
nant lymphoma.
The frequency of thrombocytopaenia and leukopaenia 
has been reported to increase when the AUC of CBDCA 
increases [3, 16, 28]. In the present study, the rate of grade 
≥3 thrombocytopaenia and neutropaenia was high in the 
AUC ≥ 4 group and particularly prominent for neutro-
paenia, which was grade ≥3 in all patients. In general, 
the frequency of grade ≥3 haemopaenia is high following 
chemotherapy for haematological cancer. Oki et al. [18] 
reported grade ≥3 neutropaenia and thrombocytopaenia in 
all cases in a study on CHASER therapy in 38 patients. In 
the present study, no difference was observed between the 
AUC ≥ 4 group (22.7 %) and the AUC < 4 group (25.7 %) 
in terms of the development of febrile neutrophilia, with 
Table 4  Changes in peripheral 
blood cell count before and after 
the first cycle of DeVIC ± R 
therapy




<4 (n = 35) ≥4 (n = 22)
Platelet (×104/μL)
 Baseline 16.8 (1.4–47.0) 18.1 (1.4–47.0) 14.3 (4.5–42.2) 0.14
 Nadir 3.0 (0.6–26.1) 4.2 (0.7–26.1) 2.7 (0.6–13.9) 0.13
Haemoglobin (μg/dL)
 Baseline 10.4 ± 2.1 10.0 ± 1.9 11.1 ± 4.9 0.045
 Nadir 8.4 ± 2.0 8.2 ± 3.6 8.5 ± 4.9 0.57
Neutrophil (/μL)
 Baseline 3290 (884–16,356) 2716 (990–15,614) 3682 (884–16,356) 0.35
 Nadir 108 (5–6384) 310 (5–6384) 47 (5–868) 0.001
Table 5  Incidence of adverse events related to peripheral blood cell 
count before and after the first cycle of DeVIC ± R therapy




<4 (n = 35) ≥4 (n = 22)
Thrombocytopaenia (%)
 <3 35.1 45.7 18.2 0.034
 ≥3 64.9 54.3 81.8
Anaemia (%)
 <3 49.1 45.7 54.5 0.52
 ≥3 50.9 54.3 45.5
Neutropaenia (%)
 <3 10.5 17.1 0 0.040
 ≥3 89.5 82.9 100.0
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both rates in the 20 % range. Avilés et al. [10] reported 
the frequencies of grade ≥3 neutropaenia after ESHAP 
and ESHAP + R therapies as 30 and 32 %, respectively, 
whereas a study conducted by Martin et al. using the same 
treatment methods [9] reported rates of febrile neutropae-
nia as 33.8 and 33.3 %, respectively. The rate of febrile 
neutropaenia in the present study was lower than that in the 
study reported by Martin et al. on ESHAP ± R therapy. Oki 
et al. [18] reported a very high rate of febrile neutropae-
nia (78 %) in a study of CHASER therapy. These numbers 
cannot be directly compared as patients and drugs included 
differed between studies; however, it is unlikely that an 
AUC cut-off value for CBDCA of ≥4 for DeVIC therapy 
increases the risk of severe haematopaenia compared with 
other treatment methods. Furthermore, we demonstrated 
that AUC of CBDCA did not influence a risk factor for 
grade 4 haematological toxicity. These findings suggest 
that setting an AUC cut-off value of ≥4 increases the risk 
of myelosuppression; however, this can be satisfactorily 
controlled clinically. However, Kewalramani et al. [16] 
reported grade 3 or 4 haematologic toxicity as the primary 
reason for delay when the target AUC of CBDCA was set 
at 5 for RICE therapy administered before autologous stem 
cell transplantation for DLBCL. A previous detailed study 
of four patients with an AUC of 5 or above reported a fre-
quency of febrile neutropaenia of 50 %. Although this find-
ing is of limited value due to the small sample size, it has 
been postulated that an AUC substantially greater than 4 
reflects an increase in the risk of severe adverse events.
There were many limitations to the present study. First, 
the small sample size of 57 reflects the low proportion of 
patients with poor responses to first-line treatment and the 
variety of treatment options for patients in such scenarios. 
This issue was avoided by the use of less strict exclusion 
criteria and multivariate analysis to increase statistical pre-
cision. Second, it was difficult to evaluate differences in 
non-haematological toxicity between the two groups due 
to the retrospective design of the present study. Third, dos-
ages of administered anti-cancer drugs other than CBDCA 
differed between patients, although we believe that this 
difference was controlled for using multivariate logistic 
regression analysis. Finally, therapeutic efficacy was evalu-
ated upon the completion of DeVIC ± R therapy, while the 
evaluation of changes in blood cell count was limited to the 
first round of treatment as administration rounds differed 
between patients.
The results of the present study indicate that the 
response rate of DeVIC ± R therapy in non-Hodgkin lym-
phoma depends on the AUC of CBDCA. We further clarify 
that the response rate increases at an AUC of ≥4. Further-
more, we suggested that an AUC of ≥4 increases the risk of 
myelosuppression; however, this can be satisfactorily con-
trolled clinically. A more efficacious target AUC value has 
been demonstrated to be 5 in ICE ± R therapy, a separate 
salvage therapy for non-Hodgkin lymphoma [16, 17]. On 
the basis of these observations, we posit an AUC of ≥4 as 
an adequate target range for AUC in DeVIC ± R therapy. 
However, as this was a retrospective study, we are unable to 
propose a specific target AUC. Further prospective studies 
using uniform conditions are required to accurately identify 
target AUCs.
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